Atypical cystic fibrosis and CFTR-related diseases

Clinical Reviews in Allergy and Immunology

Volumn 35, Issue 3, 2008, Pages 116-123

  Paranjape, Shruti M ^a   Zeitlin, Pamela L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CF transmembrane conductance regulator; Cystic fibrosis; Mutations

Indexed keywords

CHLORIDE; MACROLIDE; SODIUM; THYMIDINE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSINOGEN; CFTR PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADOLESCENCE; ADULTHOOD; AIRWAY OBSTRUCTION; ASTHMA; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHOPULMONARY ASPERGILLOMA; CHRONIC DISEASE; CHRONIC SINUSITIS; CLINICAL FEATURE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIFFUSE PANBRONCHIOLITIS; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FAILURE TO THRIVE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; MUCUS SECRETION; PANCREAS EXOCRINE INSUFFICIENCY; PATHOGENESIS; PHENOTYPE; POTENTIAL DIFFERENCE; REVIEW; STEATORRHEA; SWEAT TEST; ADOLESCENT; ADULT; ASPERGILLUS FUMIGATUS; CHEMISTRY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; LUNG ASPERGILLOSIS; METABOLISM; METHODOLOGY; MUTATION; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFECTION; SWEAT;

ADOLESCENT; ADULT; AIRWAY OBSTRUCTION; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; CHLORIDES; CHRONIC DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EXOCRINE PANCREATIC INSUFFICIENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; RESPIRATORY TRACT INFECTIONS; SWEAT;

EID: 59449091347     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-008-8083-0     Document Type: Review

References (39)

1. SD Strausbaugh PB Davis 2007 Cystic fibrosis: a review of epidemiology and pathobiology Clin Chest Med 28 279 288
2. Cystic Fibrosis Mutation Database (2007) http://www.genet.sickkids.on.ca/ cftr/app
3. MP Boyle 2003 Nonclassic cystic fibrosis and CFTR-related diseases Curr Opin Pulm Med 9 498 503
4. BJ Rosenstein GR Cutting 1998 The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Concensus Panel J Pediatr 132 589 595
5. LL Vanscoy SM Blackman JM Collaco A Bowers T Lai K Naughton M Algire R McWilliams S Beck J Hoover-Fong A Hamosh D Cutler GR Cutting 2007 Heritability of lung disease severity in cystic fibrosis Am J Respir Crit Care Med 175 1036 1043
6. J Zielenski 2000 Genotype and phenotype in cystic fibrosis Respiration 67 117 133
7. BJ Rosenstein 1994 Genotype-phenotype correlations in cystic fibrosis Lancet 343 746 747
8. JD Groman B Karczeski M Sheridan TE Robinson MD Fallin GR Cutting 2005 Phenotypic and genetic characterization of patients with features of "nonclassic" forms of cystic fibrosis J Pediatr 146 675 680
9. JD Groman ME Meyer RW Wilmott PL Zeitlin GR Cutting 2002 Variant cystic fibrosis phenotypes in the absence of CFTR mutations N Engl J Med 347 401 407
10. JE Mickle GR Cutting 1998 Clinical implications of cystic fibrosis transmembrane conductance regulator mutations Clin Chest Med 19 443 458 v
11. PG Noone MR Knowles 2001 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations Respir Res 2 328 332
12. CA Merlo MP Boyle 2003 Modifier genes in cystic fibrosis lung disease J Lab Clin Med 141 237 241
13. MP Boyle 2007 Strategies for identifying modifier genes in cystic fibrosis Proc Am Thorac Soc 4 52 57
14. A Mishra R Greaves J Massie 2007 The limitations of sweat electrolyte reference intervals for the diagnosis of cystic fibrosis: a systematic review Clin Biochem Rev 28 60 76
15. A Green P Dodds C Pennock 1985 A study of sweat sodium and chloride; criteria for the diagnosis of cystic fibrosis Ann Clin Biochem 22 Pt 2 171 174
16. KW Southern PG Noone DG Bosworth VA Legrys MR Knowles PM Barker 2001 A modified technique for measurement of nasal transepithelial potential difference in infants J Pediatr 139 353 358
17. TA Standaert L Boitano J Emerson LJ Milgram MW Konstan J Hunter PY Berclaz L Brass PL Zeitlin K Hammond Z Davies C Foy PG Noone MR Knowles 2004 Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials Pediatr Pulmonol 37 385 392
18. D Schuler I Sermet-Gaudelus M Wilschanski M Ballmann M Dechaux A Edelman M Hug T Leal J Lebacq P Lebecque G Lenoir F Stanke P Wallemacq B Tummler MR Knowles 2004 Basic protocol for transepithelial nasal potential difference measurements J Cyst Fibros 3 Suppl 2 151 155
19. KW Southern A Munck R Pollitt G Travert L Zanolla J Dankert-Roelse C Castellani 2007 A survey of newborn screening for cystic fibrosis in Europe J Cyst Fibros 6 57 65
20. MH Farrell PM Farrell 2003 Newborn screening for cystic fibrosis: ensuring more good than harm J Pediatr 143 707 712
21. Orenstein DM, Rosenstein BJ, Stern RC (2000) Cystic fibrosis: medical care. Lippincott Williams & Wilkins, Philadelphia
22. E Kerem 2006 Atypical CF and CF related diseases Paediatr Respir Rev 7 Suppl 1 S144 146
23. KW Southern 2007 Cystic fibrosis and formes frustes of CFTR-related disease Respiration 74 241 251
24. JA Cohn KJ Friedman PG Noone MR Knowles LM Silverman PS Jowell 1998 Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis N Engl J Med 339 653 658
25. PF Pignatti C Bombieri M Benetazzo A Casartelli E Trabetti LS Gile LC Martinati AL Boner M Luisetti 1996 CFTR gene variant IVS8-5T in disseminated bronchiectasis Am J Hum Genet 58 889 892
26. E Girodon C Cazeneuve F Lebargy T Chinet B Costes N Ghanem J Martin S Lemay P Scheid B Housset J Bignon M Goossens 1997 CFTR gene mutations in adults with disseminated bronchiectasis Eur J Hum Genet 5 149 155
27. M Luisetti PF Pignatti 2003 Genetics of idiopathic disseminated bronchiectasis Semin Respir Crit Care Med 24 179 184
28. X Wang B Moylan DA Leopold J Kim RC Rubenstein A Togias D Proud PL Zeitlin GR Cutting 2000 Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population JAMA 284 1814 1819
29. V Raman R Clary KL Siegrist B Zehnbauer TA Chatila 2002 Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis Pediatrics 109 E13
30. PW Miller A Hamosh M Macek Jr PA Greenberger J MacLean SM Walden RG Slavin GR Cutting 1996 Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis Am J Hum Genet 59 45 51
31. M Dahl A Tybjaerg-Hansen P Lange BG Nordestgaard 1998 DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma Lancet 351 1911 1913
32. P King 2007 Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 67 965 974
33. BK Rubin MO Henke 2004 Immunomodulatory activity and effectiveness of macrolides in chronic airway disease Chest 125 70S 78S
34. MS Schechter 2007 Airway clearance applications in infants and children Respir Care 52 1382 1390 discussion 1390-1381
35. Wills P, Greenstone M (2006) Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev CD002996
36. BK Rubin 2006 Other medications for aerosol delivery Paediatr Respir Rev 7 Suppl 1 S76 79
37. S Akai H Okayama S Shimura Y Tanno H Sasaki T Takishima 1992 Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan Am Rev Respir Dis 146 781 783
38. V Poletti G Casoni M Chilosi M Zompatori 2006 Diffuse panbronchiolitis Eur Respir J 28 862 871
39. MR Knowles PR Durie 2002 What is cystic fibrosis? N Engl J Med 347 439 442